Compared with placebo , lasofoxifene 0.5 mg/d reduced the risk of major CHD events 32 % ( hazard ratio , 0.68 ; 95 % confidence interval , 0.50 to 0.93 ) , including the risk of coronary revascularization ( hazard ratio , 0.56 , 95 % confidence interval , 0.32 to 0.98 ) .
